Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Neha Panjwani

Is DexCom Stock Underperforming the S&P 500?

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems. Valued at $24.8 billion by market cap, the company develops a small implantable device that continuously measures glucose levels in subcutaneous tissue just under the skin and a small external receiver to which the sensor transmits glucose levels at specified intervals.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and DXCM perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the medical devices industry. DexCom leads in diabetes care with its advanced CGM systems like G6 and G7, driving innovation and convenience. Strategic partnerships with insulin pump companies enhance its offerings and market reach, solidifying its position in the growing diabetes market.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.